Quarterly ResultAug 6, 2026, 04:10 PM
Aldeyra Therapeutics Q2 Net Loss Narrows to $5.45M; Repays $15M Debt
AI Summary
Aldeyra Therapeutics reported a net loss of $5.45 million, or $(0.09) per share, for the second quarter of 2026, a significant improvement from the $9.77 million net loss in the same period last year. The company successfully repaid its $15.0 million outstanding debt principal on April 1, 2026. As of June 30, 2026, cash and cash equivalents stood at $45.09 million, and the company is evaluating a securities class action lawsuit filed in March 2026.
Key Highlights
- Net loss for Q2 2026 was $5.45 million, down from $9.77 million in Q2 2025.
- Net loss per share for Q2 2026 was $(0.09), compared to $(0.16) in Q2 2025.
- Repaid $15.0 million outstanding debt principal on April 1, 2026.
- Cash and cash equivalents totaled $45.09 million as of June 30, 2026.
- Research and development expenses decreased to $3.48 million in Q2 2026.
- General and administrative expenses increased to $2.37 million in Q2 2026.
- A securities class action lawsuit was filed on March 30, 2026.
- Company believes current cash is sufficient for at least the next 12 months.
Price Impact
More from ALDX